.After raising $170 million back in February, metabolic disease-focused BioAge Labs has actually filed to debut on the general public market.The Eli Lilly-partnered biotech wish to list on the Nasdaq under the icon "BIOA," according to files filed with the Securities and Swap Commission. The business has certainly not openly discussed an assumed financial volume for the offering.The clinical-stage business touts lead candidate azelaprag, a by mouth provided little particle slated to get in period 2 screening in combination along with semaglutide-- sold through Novo Nordisk under brand name Wegovy for fat burning-- in the very first one-half of next year. Semaglutide is actually likewise sold as Ozempic and Rybelsus through Novo for diabetes mellitus.
Apelin receptor agonist azelaprag is actually developed to integrate well along with GLP-1 medications, boosting weight reduction while maintaining muscle mass. The investigational drug was actually found to become well-tolerated amongst 265 people around eight phase 1 tests, according to BioAge.Recently, BioAge amassed the help of Lilly to manage a trial blending azelaprag with the Large Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is industried for diabetic issues as Mounjaro and also Zepbound for weight management. The partners are actually currently conducting a period 2 trial of azelaprag and also tirzepatide, with topline results expected in the 3rd one-fourth of 2025.The biotech is actually additionally preparing an insulin sensitiveness proof-of-concept test determining azelaprag as a monotherapy in the 1st half of upcoming year to sustain possible indication expansion. Moreover, the business intends to inquire the FDA for permission in the second fifty percent of 2025 to introduce human screening for an NLRP3 inhibitor targeting metabolic illness and neuroinflammation.BioAge's foreseed relocate to everyone market follows a slight uptick in planned biotech IPOs coming from Bicara Therapies as well as Zenas Biopharma. Zooming out, the current IPO landscape is a "mixed photo," along with high quality companies still debuting on everyone markets, only in minimized numbers, according to PitchBook.